Navigation Links
Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook
Date:2/8/2011

hat its business model delivers results; the company's expectation that growth in top-line revenue will be driven almost exclusively by increasing adoption of its breast cancer test; the company's ability to accelerate the development of a test for prostate cancer and the potential timing of the launch of a new test for prostate cancer; the  success or results of clinical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; our success retaining current contracts or levels of reimbursement coverage for our tests; the risks and uncertainties associated with the regulation of our tests by FDA; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to successfully commercialize our products outside of the US; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health l
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015  SynCardia Systems, Inc. has received FDA approval ... on the effective use of its 50cc SynCardia temporary ... The FDA approval will allow SynCardia to ... failure patients. Patients enrolled in this study will receive ... to a donor heart transplant. (Caution-In the United ...
(Date:3/31/2015)... March 31, 2015 MedSpring Urgent Care is pleased to ... Dallas/Fort-Worth area of Upper Greenville. The center – located ... Dallas location. Knox - Henderson ... the surrounding community since opening last fall. Additional Dallas ... Keller and Las Colinas neighborhoods this summer. ...
(Date:3/31/2015)... AVIV, Israel, March 31, 2015  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, today announced ... 31, 2014. Fourth Quarter 2014 Highlights: ... featuring a keynote address by Professor Rohit Loomba, ...
Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8
... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
... Invasive Surgery at St.,Luke,s-Roosevelt Hospital Center completes his ... benefiting from ,hidden scar, procedure, CUPERTINO, Calif., ... completion of a series of single port Lap-Band,procedures ... pain for,patients. Dr. Julio Teixeira at St. Luke,s-Roosevelt ...
Cached Medicine Technology:Clinical Lab Products Magazine Features Biomoda 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 3
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... 31, 2015 Safeware has ... Employers in Central Ohio, an awards program presented by ... winners of the awards program, held on March 10, ... to employee health, with outstanding health and wellness initiatives. ... to creating a healthy environment for their associates. Business ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... Italy (PRWEB) March 31, 2015 A' ... the design project Bruker EVOQ by Daniel Dion has ... Design Award in Scientific Instruments, Medical Devices and ... EVOQ, Daniel Dion, the creative mind behind the award ... EVOQ MS - developed under the direction of Dr. ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... , RESTON, Va., Aug. 11 ... the digital world, today released a study of the online health ... online consumer activity. While the number of visitors to health insurance ... increase in the number of searches related to obtaining health coverage ...
... engineered white blood cells could include drug testing, researchers ... new technique that transforms embryonic and adult stem cells ... produce blood cells with specific defects for use by ... The method, devised by University of Wisconsin-Madison researchers, could ...
... study conducted at the Jefferson Headache Center at ... an investigational, orally-inhaled therapy is effective in treating ... for the orally-inhaled migraine therapy, LEVADEX, shows study ... pain, nausea and light and sound sensitivity when ...
... NewYork-Presbyterian Hospital/Weill Cornell Medical Center will create a New York ... treatment for elder abuse cases in the New York City ... focus on coordinating elder abuse cases, the Center has received ... Leslie R. Samuels Foundation and $75,250 from the FJC, A ...
... , WASHINGTON, Aug. 11 The Partnership to ... care provisions contained within health reform legislation passed out of committee. ... be improved to increase quality of care and reduce health care ... other legislation is introduced, specifically the Senate Finance Committee plan. , ...
... , , LAKE FOREST, Ill., Aug. ... leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug ... States. The medication is a generic version of Sanofi-Aventis, Eloxatin(R), which ... is one of the first generic versions of this drug to ...
Cached Medicine News:Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3Health News:Stem Cell Advance May Further Disease Research 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 3Health News:Partnership to Fight Chronic Disease Analyzes Key Provisions in Health Care Legislation Released To-Date 2Health News:Hospira Launches Generic Oxaliplatin Injection 2Health News:Hospira Launches Generic Oxaliplatin Injection 3
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
... are available in three styles ... available non-sterile and sterile, and ... Depending on the patient needs, ... or two implants (medial and ...
Medicine Products: